NCT00421473已完成4 期
Drug Interactions Between ATOvaquone Used in MAlaria Prophylaxis and Antiretroviral Agents in HIV-1 Infected Patients (ATOMA)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 10
- 主要终点
- Pharmacokinetic blood samples will be taken just before dosing Malarone, and 12 samples in the time between 0,5 hour and 168 hours after dosing.
研究概览
简要总结
Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism.
For travelling HIV patients, the clinical consequences of these possible drug drug interactions are serious, since a diminished exposure to the anti-malarial drug will result in suboptimal prophylaxis of malaria and potential development of drug resistant strains of Plasmodium falciparum.
The purpose of this study is to find out if HIV patients using HAART regimes with either lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels than healthy volunteers after a single dose of atovaquone/proguanil.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For healthy volunteers
- •18 - 65 years
- •smoking habits < 10 cigarettes, 2 cigars or 2 pipes
- •BMI between 18 and 30 kg/m2
- •able and willing to sign informed consent form
- •subject is in a good age-appropriate health condition
- •subject has a normal blood pressure and pulse rate
- •For HIV patients
- •HIV-infected as documented by positive HIV antibody test and confirmed by Western Blot.
- •CD4+ > 200 * 10E6 per Liter.
- •18 - 65 years
- •BMI between 18 and 30 kg/m2
- •able and willing to sign informed consent form
- •use of lopinavir/ritonavir, atazanavir/ritonavir or efavirenz for at least 1 month in a dose of 400/100mg bid, 300/100 mg QD, or 600 mg QD respectively
- •Exclusion Criteria healthy volunteers:
- •History of sensitivity/idiosyncrasy to atovaquone/proguanil or chemically related compounds or excipients.
- •Positive HIV test.
- •Positive HbsAg test (hepatitis B) or positive hepatitis C test.
- •Therapy with any drug (for two weeks preceding dosing), except for paracetamol.
- •Creatinine clearance < 60 mL/min (calculated from serum creatinine)
- •Current diarrhoea.
- •Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •History of or current abuse of drugs, alcohol or solvents.
- •Inability to understand the nature and extent of the trial and the procedures required.
- •Participation in a drug trial within 60 days prior to the first dose.
- •Donation of blood within 60 days prior to the first dose.
- •Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female.
- •Abnormal serum transaminases, determined as levels being > 3 times up-per limit of normal
- •Febrile illness within 3 days before the first dose
- •Exclusion criteria HIV patients:
- •History of sensitivity/idiosyncrasy to atovaquone/proguanil or chemically related compounds or excipients.
- •Suspicion of non-adherence to the HIV medication.
- •Current diarrhoea.
- •Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •Inability to understand the nature and extent of the trial and the procedures required.
- •Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female.
- •Abnormal serum transaminases determined as levels being > 3 times upper limit of normal
- •Creatinine clearance < 60 mL/min (calculated from serum creatinine).
- •Any change in antiretroviral medication within 1 month immediately pre- ceding the dose of atovaquone/proguanil.
- •Concomitant use of medications that interfere with atovaquone or proguanil pharmacokinetics: anti-coagulants, aurothioglucose, chloroquine, cimetidine, fluoxetine, fluvoxamine, metoclopramide, omeprazole, magnesiumtrisilicate, rifabutin, rifampin, tetracycline, typhoid vaccine, topiramate.
- •Use of a HAART regime containing both lopinavir/ritonavir and another protease inhibitor or a NNRTI.
- •Use of a HAART regime containing both atazanavir/ritonavir and another protease inhibitor or a NNRTI.
- •Use of a HAART regime containing both efavirenz and one or more protease inhibitors or nevirapine.
- •Active hepatobiliary or hepatic disease
- •Alcohol abuse
排除标准
- 未提供
结局指标
主要结局
Pharmacokinetic blood samples will be taken just before dosing Malarone, and 12 samples in the time between 0,5 hour and 168 hours after dosing.
次要结局
- Blood will be taken for genotyping of CYP2C19 at study day 1.
- HIV-1 RNA and CD4 determination will be done (HIV patients only) at inclusion screening
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Weekly Dosing of Malarone ® for Prevention of MalariaMalariaNCT00984256U.S. Army Medical Research and Development Command35
已完成
4 期
Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected AdultsHIVMalariaNCT00790881University of Cape Town36
已完成
4 期
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected AdultsMalariaHIV InfectionsNCT00869700University of Cape Town18
已完成
4 期
Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic AcidOral AnticoagulationAtrial FibrillationDeep Venous ThrombosisPulmonary EmbolismNCT00603317Assistance Publique - Hôpitaux de Paris13
已完成
2 期
Methylene Blue Against Falciparum Malaria in Burkina FasoMalaria, FalciparumNCT02851108Heidelberg University100